Raise closed, search for fresh raises on Seedstage

Carlsbad, CA

Developing advanced qPCR and NGS technologies to simplify genomic workflows and expand market reach.

• Proven Revenue Generation: Over $45 million in revenue with minimal outside investment.
• Innovative Technologies: Launched nine products, including two novel, patent-protected platforms.
• Diversified Market Presence: Serving clinical labs, biotech firms, pharmaceuticals, and academic institutions.
• Strong Intellectual Property: Patent coverage across the US, EU, and China.
• Strategic Growth Plan: Focused on expanding manufacturing, increasing margins, and developing next-gen technologies.

SeqOnce Biosciences is an innovative biotechnology company aiming to revolutionize the $34 billion genomics market through its advanced qPCR, Next Generation Sequencing (NGS), and novel molecular biology platforms. Founded to simplify and enhance NGS sample preparation, SeqOnce has since diversified its offerings to include qPCR assays for pathogen screening and women’s health, and its proprietary RhinoSeq technology for rapid DNA library preparation. With a strategic pivot during the pandemic, the company developed qPCR reagents for COVID-19 testing, generating over $45 million in revenue to date. Building on this success, SeqOnce has launched nine products and introduced two new patented technologies, including NICER, designed to disrupt the qPCR market with faster and more efficient workflows.

SeqOnce operates on a B2B model, serving clinical labs, biotech companies, pharmaceuticals, government labs, and academic institutions. Its products are known for their quality, reliability, and ease of integration, which fosters long-term client relationships due to the high cost and complexity of switching suppliers. The company plans to use new funding to expand internal manufacturing, increase margins, grow its commercial infrastructure, and further develop its NICER technology and additional qPCR and NGS assays. With established global patent protection and a robust supply chain, SeqOnce is positioned for substantial growth, aiming to increase enterprise value ahead of a future Series A round or IPO.

Company Info

SeqOnce Biosciences is transforming the genomics market with innovative technologies that simplify DNA sample preparation for clinical, biotech, and academic labs, while also expanding into DTC markets.

SeqOnce Biosciences is a DeepTech company focused on revolutionizing the $34 billion genomics market. With a strong portfolio in qPCR (quantitative PCR), Next Generation Sequencing (NGS), and NICER technologies, SeqOnce aims to simplify and improve the efficiency of DNA sample preparation, making advanced genomic processes more accessible. Initially pivoting during the COVID pandemic, SeqOnce developed and sold qPCR reagents for COVID tests, and today, they continue to innovate, developing products for respiratory pathogens, women’s health, and pathogen screening. The company has generated over $45 million in revenue, with a current run rate of $100,000 to $250,000 per month, and boasts patent protections across the US, EU, and China.

SeqOnce’s technology platforms, including RhinoSeq (a fast library prep for NGS) and NICER (a novel molecular biology platform), are positioned to disrupt the genomics market by reducing sample preparation time and enhancing the accessibility of Next Generation Sequencing. With a minimal outside investment, a clean cap table, and a strong customer base, the company is looking to expand its reach in both direct-to-consumer (DTC) and clinical markets. SeqOnce aims to build a commercial infrastructure to ramp up sales and continue developing groundbreaking technologies to solidify its leadership in the genomics sector.